Ervebo Vaccine

Indications

• Ebola virus disease
• Supportive treatment for Ebola virus infection

Dosage

Children: Refer to specific treatment guidelines for Ebola virus disease in children.

Adults: Refer to specific treatment guidelines for Ebola virus disease.

Mechanism of action

Ebola virus primarily infects macrophages and dendritic cells, leading to impaired immune response and significant inflammatory responses. The virus enters host cells via receptor-mediated endocytosis, where it releases its genetic material into the cytoplasm. The viral proteins interfere with host cell signaling pathways, inhibiting the production of type I interferons, which are crucial for antiviral defense. This evasion of immune response contributes to the virus's virulence.

Pharmacodynamics

Ebola virus infection leads to a rapid and severe inflammatory response, often resulting in multi-organ failure. The dysregulation of the immune response can cause a cytokine storm, leading to increased vascular permeability, shock, and coagulopathy. The disease progression can be exacerbated by the systemic inflammatory response, which can result in significant tissue damage and organ dysfunction.

Pharmacokinetics

Pharmacokinetic data specific to Ebola virus treatments can vary widely depending on the specific therapeutic agent used. However, treatments may involve monoclonal antibodies, antiviral agents, or supportive care. The metabolism and excretion of these agents depend on their specific mechanisms and pathways. For example, monoclonal antibodies may have prolonged half-lives due to their nature of being proteins, while antiviral agents may be metabolized by the liver and excreted via the kidneys.

Adverse effects

• Fever
• Fatigue
• Diarrhea
• Vomiting
• Abdominal pain
• Muscle pain
• Headache
• Hemorrhagic manifestations
• Rash
• Conjunctivitis

Precautions

• Use caution in patients with a history of severe allergic reactions.
• Implement strict infection control measures due to the highly contagious nature of the virus.
• Monitor for signs of bleeding or organ failure.

Pregnancy

Ebola virus infection in pregnancy poses significant risks, including miscarriage and maternal mortality. It is crucial to evaluate the risks and benefits before any treatment.

Breast-feeding

Breastfeeding is not recommended during Ebola virus infection due to the risk of transmission through breast milk.

Storage

Ebola virus is a highly infectious pathogen and should be handled in a biosafety level 4 facility. Specimens need to be stored and transported under strict containment protocols.

Indications

• Prevention of infectious diseases such as measles, mumps, rubella, hepatitis B, influenza, and human papillomavirus (HPV)
• Travel vaccinations for diseases endemic to certain regions
• Vaccination for at-risk populations, such as those with compromised immune systems or specific occupational exposures

Dosage

Children: Dosage varies by vaccine type and age; refer to the BNF for Children for specific dosing information.

Adults: Dosage varies by vaccine type and indication; refer to specific guidelines for each vaccine.

Mechanism of action

Vaccines work by mimicking an infection. They introduce a harmless component of a pathogen (antigen) to the immune system, prompting the body to produce an immune response. This includes the generation of antibodies and memory cells that provide long-term immunity. Upon subsequent exposure to the actual pathogen, the immune system is primed to respond more rapidly and effectively.

Pharmacodynamics

The pharmacodynamics of vaccines involves the activation of both humoral and cellular immunity. Vaccines stimulate B cells to produce antibodies against the pathogen, while T cells are activated to destroy infected cells. This dual response helps to establish immunological memory, which enables a faster and more robust response upon re-exposure to the pathogen.

Pharmacokinetics

Vaccines are administered via various routes, including intramuscular, subcutaneous, and oral. After administration, the antigens are presented to antigen-presenting cells, which activate T cells and stimulate B cell proliferation and differentiation. The half-life of vaccine-induced immunity varies depending on the type of vaccine, with some providing lifelong immunity and others requiring booster doses to maintain protection.

Contra-indications

• Severe allergic reaction (anaphylaxis) to a component of the vaccine
• Severe immunocompromised state for live attenuated vaccines

Adverse effects

• Local reactions at the injection site (pain, redness, swelling)
• Fever
• Fatigue
• Headache
• Muscle pain
• Joint pain
• Nausea

Interactions

• Immunosuppressive medications may reduce vaccine efficacy
• Concurrent administration of some vaccines may require spacing to optimize immune response

Precautions

• History of allergic reactions to vaccines or vaccine components
• Pregnancy (specific vaccines may be contraindicated)
• Moderate to severe acute illness with or without fever

Pregnancy

Consult healthcare provider. Some vaccines are contraindicated during pregnancy, while others are recommended.

Breast-feeding

Generally considered safe, but consult healthcare provider regarding specific vaccines.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Liquid suspension for injection
• Lyophilized powder for reconstitution

Indications

• Ebola virus disease caused by Zaire ebolavirus
• Post-exposure prophylaxis in high-risk individuals
• Treatment of confirmed Ebola cases

Dosage

Children: Refer to specific antiviral treatment guidelines for pediatric dosing information, as doses can vary based on the medication used.

Adults: Refer to specific antiviral treatment guidelines for dosing information, as doses can vary based on the medication used.

Mechanism of action

The Zaire ebolavirus primarily infects host cells by binding to specific receptors on the cell surface, leading to viral entry via macropinocytosis. Once inside, the virus hijacks the host cell's machinery to replicate its RNA and produce viral proteins. The newly formed virions are then released from the host cell, allowing for further infection of adjacent cells. This cycle of infection leads to widespread cell death and immune system dysregulation.

Pharmacodynamics

The pharmacodynamics of antiviral treatments for Zaire ebolavirus involve the inhibition of viral replication and the modulation of the host immune response. Some therapeutic agents target viral proteins or RNA synthesis, while others aim to enhance immune responses to control and eliminate the infection. The effectiveness of such treatments can vary depending on the timing of administration and the severity of the disease.

Pharmacokinetics

The pharmacokinetics of antiviral treatments for Ebola, including those targeting the Zaire strain, often involve rapid absorption, distribution, metabolism, and excretion, although specific parameters can vary widely depending on the drug. Generally, these agents are administered intravenously or orally and are distributed widely in body tissues. Metabolism may occur in the liver, and excretion is typically via urine. The half-life and clearance rates can differ based on the specific antiviral used.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and the benefits outweigh the risks.

Breast-feeding

It is unknown whether this drug is excreted in human milk. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.